Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Most patients with inflammatory bowel diseases (IBD) are offered conventional medical therapy, because emerging therapies for IBD are regulated by health-care jurisdiction and often limited to academic centres. This review distils current evidence to provide a pragmatic approach to conventional IBD therapy, including aminosalicylates, corticosteroids, thiopurines, methotrexate, calcineurin inhibitors, infliximab and adalimumab. It addresses drug efficacy, safety and salient practice points for optimal and appropriate practice.

Original publication




Journal article


Scand J Gastroenterol

Publication Date





90 - 112


Crohn’s disease, inflammatory bowel disease, ulcerative colitis, Anti-Bacterial Agents, Anti-Inflammatory Agents, Antibodies, Monoclonal, Gastrointestinal Agents, Humans, Immunosuppressive Agents, Inflammatory Bowel Diseases, Practice Guidelines as Topic, Treatment Outcome